REHOVOT, Israel, Dec. 17,
2024 /PRNewswire/ -- Amai Proteins, a scale-up
designer of novel proteins that answer the needs of consumers and
industry, has succesfullly completed world's first double-blind,
random clinical trial on the effects of their proprietary
hyper-sweet protein, sweelin®, on blood glucose and insulin levels
in humans.
The study demonstrated that sweelin® neither raises blood
glucose nor blood insulin levels in healthy adults even after
consuming an amount equivalent to the sweetness of 75 grams of
sugar (in the form of glucose).
Although not required by regulatory authorities, Amai
Proteins decided to conduct this study to boost consumer and
market confidence in the safety and health profile of sweelin®. The
study provides validated evidence of the beneficial effects of
sweelin® on consumer's health. sweelin® can help consumers globally
who are trying to reduce added sugars in their diet but don't want
to compromise on taste or health.
The study was conducted at the Phase 1 Clinical Research Center
(CRC) of Tel Aviv Sourasky Medical Center, under strict Good
Clinical Practice (GCP) standards. Twenty eligible healthy
volunteers completed the screening process and participated in the
study.
All participants made three visits to the medical center. During
each visit, the participants consumed one of three test beverages
sweetened by either sweelin®, glucose, or stevia in a crossover
double-blind, randomized controlled manner. All beverages were
matched for sweetness intensity, with their dosage aligned to the
sweetness equivalent of 75 grams of glucose, as used in a standard
Oral Glucose Tolerance Test (OGTT). The study monitored the
participants' response to the test beverages for 120 minutes after
consumption, measuring postprandial blood glucose and insulin
levels.
All the participants successfully completed the study with no
test-item-related adverse events, and no dropouts.
For the first time, this study by Amai proteins confirmed that a
high dose of sweelin®, which can be labelled as 'serendipity berry
sweet protein', does not impact blood glucose or insulin levels in
healthy individuals.
About Amai Proteins
Amai Proteins develops novel proteins which answer the needs of
consumers and industry. Our first product, sweelin®, is a
calorie-free sweet protein designed to significantly replace sugar
and sugar alternatives in a wide variety of food & beverages
including soft drinks, fruit juice, dairy products, sauces,
spreads, dressings, snacks, peanut butter, and much more. Our
solutions are inspired by nature and built with biology through a
natural fermentation process. With our Pro3 platform,
Amai Proteins aims to create future breakthroughs in the world of
meat, plant and milk proteins.
www.amaiproteins.com or visit our official LinkedIn and
YouTube channels.
For more on sweelin®, visit sweelin.com
For more information:
Dr. Ilan Samish, Founder &
CEO, Amai Proteins
press@amaiproteins.com
Video - https://www.youtube.com/watch?v=nFx1yM-8qL0
Video - https://youtu.be/8p58pIhJi-I
Logo - https://mma.prnewswire.com/media/2529725/sweelin.jpg
Logo - https://mma.prnewswire.com/media/2529724/Amai.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/amai-proteins-succesfully-completed-worlds-first-human-clinical-trial-on-effects-of-sweet-proteins-with-sweelin-302332539.html